Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BUSINESS BITES: Tissue Regenix Sets Up JV For Heart Valve, Skin Graft Sales; bioTheranostics Stands On Its Own; Hello Trividia

This article was originally published in Clinica

Executive Summary

UK regenerative medicine specialist Tissue Regenix (TRX) is setting up a joint venture in Germany with Rostock-based tissue bank GTM-V to commercialize its dCell replacement heart valves and DermaPure skin graft products in Europe. The products are manufactured using TRX’s dCell technology for decellularizing tissue. DermaPure is already sold in over 30 states the US but is not yet available in the EU. The joint venture, called GBM-V, will prepare regulatory submissions to the German authorities to obtain the required approvals for the products. The first products are targeted to be launched in 2017. “Germany is particularly stringent with its human tissue regulations, which provides a high benchmark from which wider EU approvals can follow,” said Antony Odell, CEO of TRX. Odell and Frank Peter Nitschke will be joint CEOs of GBM-V.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel